The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation to obecabtagene autoleucel (Autolus Therapeutics; brand name AUCATZYL) for the treatment of adults aged 18 years and over with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL). The authorisation, granted in April 2025, makes obecabtagene autoleucel the first CAR T-cell therapy licensed in the UK specifically for this indication and follows an equivalent decision by the United States Food and Drug Administration (FDA) in November 2024.
Obecabtagene autoleucel is a next-generation autologous CD19-directed chimeric antigen receptor T-cell therapy developed at UCL Cancer Institute under the laboratory of Dr Martin Pule before its commercial development through Autolus Therapeutics, a UCL spinout incorporated in 2014. Its UK authorisation is the company's first MHRA marketing authorisation and positions the therapy within an NHS advanced therapy medicinal products pathway that now awaits a National Institute for Health and Care Excellence (NICE) technology appraisal before routine commissioning can proceed.
What the MHRA Authorisation Covers
The marketing authorisation applies to adult patients with B-cell precursor acute lymphoblastic leukaemia whose disease has relapsed following prior therapy or has proven refractory to treatment. B-ALL is an aggressive haematological malignancy characterised by uncontrolled proliferation of immature B-lymphocyte precursors in the bone marrow, peripheral blood, and, in some cases, the central nervous system. For adults, outcomes with standard salvage chemotherapy remain poor, with complete remission rates in the relapsed or refractory setting typically ranging from 20% to 45% depending on prior therapy exposure and cytogenetic risk profile.
The authorisation follows the standard MHRA review process for conditional and full marketing authorisations, and the pivotal clinical dataset supporting the decision was the FELIX study a multi-centre, single-arm trial conducted in adult patients with r/r B-ALL. The MHRA's decision to grant authorisation on the basis of the FELIX dataset reflects the agency's assessment that the benefit-risk profile is favourable in a patient population with limited licensed treatment options.
The authorisation does not constitute NHS availability. A manufacturing authorisation and a NICE technology appraisal are separate requirements before obecabtagene autoleucel can be offered routinely to eligible NHS patients in England. Scotland will require a separate decision from the Scottish Medicines Consortium (SMC).
How Obecabtagene Autoleucel Works
Obecabtagene autoleucel is an autologous CAR T-cell therapy, meaning it is manufactured from the patient's own T-lymphocytes rather than from a donor source. The manufacturing process begins with leukapheresis, during which T-cells are collected from the patient's peripheral blood. These T-cells are then genetically modified ex vivo to express a chimeric antigen receptor designed to recognise the CD19 protein, which is expressed on the surface of B-cell precursors and on the leukaemic blasts in B-ALL.
The CAR construct used in obecabtagene autoleucel incorporates a fast-off kinetic design, which is a clinically meaningful technical distinction from earlier first-generation CD19-directed CAR T-cell therapies. In standard CD19 CAR T constructs, the single-chain variable fragment (scFv) binds CD19 with high affinity and prolonged dwell time. This sustained binding can trigger tonic CAR signalling during the manufacturing phase, which drives T-cell exhaustion before the cells are infused and limits in vivo persistence after infusion. The obecabtagene autoleucel construct uses a modified scFv with reduced CD19-binding affinity, producing a faster dissociation rate. This design reduces tonic signalling, maintains a less-exhausted T-cell phenotype at the point of infusion, and is hypothesised to improve persistence and functional activity in vivo.
Following infusion, CAR-expressing T-cells recognise and bind CD19-positive leukaemic blasts, triggering cytotoxic T-cell activation, targeted cell killing, and the release of cytokines including interferon-gamma and interleukin-2. The same mechanism that produces anti-tumour activity also drives the principal adverse effects: cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Both are well-characterised class effects of CD19-directed CAR T-cell therapy and require active management in accredited treatment centres with appropriate intensive care support.
Real fact: CD19 is expressed on approximately 95% of B-cell precursor acute lymphoblastic leukaemia blasts, making it the most widely targeted antigen in B-ALL immunotherapy and the basis for multiple approved CAR T-cell and bispecific antibody programmes.
What the FELIX Trial Showed
The FELIX study was a multi-centre, single-arm, open-label Phase 2 trial evaluating obecabtagene autoleucel in adult patients with r/r B-ALL. The pivotal cohort enrolled 94 patients who had received at least one prior line of therapy and whose disease had relapsed or proven refractory. Results from the pivotal cohort were published in the New England Journal of Medicine in November 2024.
The primary efficacy endpoint was overall complete remission rate, defined as complete remission (CR) plus complete remission with incomplete haematological recovery (CRi) within the first 24 weeks following infusion. In the pivotal cohort, 77% of patients achieved overall complete remission, a result that substantially exceeded the pre-specified threshold and compared favourably with complete remission rates reported with standard salvage regimens and with inotuzumab ozogamicin (Besylemi), the only other drug licensed for r/r B-ALL in adults.
As a single-arm trial, the FELIX study was not powered for direct comparative analysis with an active control, and no randomised comparison with inotuzumab ozogamicin or blinatumomab (Blincyto) was conducted. This is a substantive limitation: in the absence of a randomised head-to-head dataset, the relative efficacy of obecabtagene autoleucel versus licensed comparators in this indication cannot be established from the available evidence. The MHRA's benefit-risk assessment necessarily relied on single-arm data and historical comparator benchmarks, a regulatory approach that is standard for advanced therapies in rare or ultra-rare populations but that carries uncertainty the treating haematologist must weigh.
Overall survival and event-free survival data from the FELIX cohort were reported at MHRA submission, with median duration of complete remission exceeding 24 months in a subset of responders, a clinically meaningful durability signal in a disease where durable remission with salvage chemotherapy is uncommon. However, the study represents interim rather than final analysis data at the point of the MHRA decision, and long-term follow-up remains ongoing. As of the November 2023 data cutoff reported in the primary publication, some responders had maintained complete remission for over 47 months.
Adverse events in the FELIX trial reflected the established CAR T-cell safety profile. CRS occurred in the majority of treated patients; the proportion experiencing Grade 3 or higher CRS was lower than rates reported with some earlier CD19-directed CAR constructs, which the investigators attributed in part to the fast-off kinetic design reducing peak cytokine output. ICANS was observed in a clinically meaningful proportion of patients and required management with corticosteroids and, in some cases, intensive care support. The FELIX trial was conducted at accredited CAR T-cell therapy centres; the manufacturing, administration, and monitoring requirements mean that obecabtagene autoleucel will only be available at NHS Trusts with existing JACIE-accredited cell therapy programmes.
Regulatory Context and UK Pathway
The MHRA marketing authorisation follows the agency's standard scientific assessment process for advanced therapy medicinal products. The manufacturing site for obecabtagene autoleucel the Centre for Cell, Gene and Tissue Therapeutics at Royal Free Hospital was a factor in the UK development pathway, giving the therapy a domestic manufacturing footprint that is relevant to NHS supply chain considerations.
The FDA approval in November 2024 preceded the MHRA decision. In the post-Brexit regulatory environment, the MHRA conducts its own independent assessment and is not bound by FDA or EMA decisions, although it may consider the conclusions of other regulators as part of its review. An application to the European Medicines Agency (EMA) was accepted for review in March 2024 and remains under assessment as of the MHRA authorisation date. If EMA grants a marketing authorisation, the EU decision will not automatically apply in the UK a consequence of regulatory divergence that now requires separate NHS access processes for any therapy authorised in both jurisdictions.
For the NHS pathway, the next formal milestone is NICE completing its technology appraisal. . Until NICE publishes its guidance and NHS England confirms a commissioning position, obecabtagene autoleucel cannot be offered routinely to eligible patients. Patients may seek access through a managed access scheme or through individual funding requests while the NICE process is completed both routes are slower, less consistent, and not guaranteed.
The SMC will conduct its own assessment for Scotland, and the All Wales Medicines Strategy Group (AWMSG) may do likewise for Wales. The timeline for these assessments is independent of the NICE process.
Clinical Implications for NHS Haematology Practice
The MHRA authorisation of obecabtagene autoleucel expands the licensed options for adult r/r B-ALL in the UK. Before this authorisation, the licensed landscape for adults included inotuzumab ozogamicin (CD22-directed antibody-drug conjugate, MHRA authorised under EMA CHMP opinion) and blinatumomab (CD19/CD3 bispecific T-cell engager). These agents operate through different mechanisms and are often used sequentially in current UK practice. Obecabtagene autoleucel's one-time infusion design, in contrast to the continuous or intermittent infusion schedules of blinatumomab and inotuzumab ozogamicin respectively, may offer a practical advantage in patients fit enough for a cell therapy protocol though direct comparative data do not currently exist.
Clinical selection will depend on patient fitness for lymphodepletion chemotherapy, CAR T-cell manufacturing feasibility, centre accreditation, and individual disease characteristics including prior treatment history, MRD status, and cytogenetic risk profile. The subset of patients with Philadelphia chromosome-positive B-ALL require particular consideration given the role of tyrosine kinase inhibitors in this population.
What to Watch For
The immediate next milestone is NICE completing its technology appraisal and issuing guidance on NHS commissioning. The NICE assessment will involve a full cost-effectiveness analysis, and given the high per-patient cost characteristic of cell therapies, a managed access scheme or commercial access agreement with Autolus Therapeutics is likely to form part of any positive recommendation. Prescribers at JACIE-accredited centres should track the NICE appraisal timeline and ensure their institutions are registered as potential treatment sites. EMA's decision on the marketing authorisation application submitted in March 2024 is also expected within the coming months and will influence the therapy's European access position.
The FELIX dataset remains at interim analysis stage, and long-term overall survival data will mature over the next two to three years. Whether the complete remission durability signal translates into survival benefit at five years, the benchmark that most influences NICE cost-effectiveness modelling, will determine whether this authorisation consolidates into a routine NHS treatment or remains a conditional, tightly managed option. The fast-off kinetic design hypothesis is compelling, but it requires validation against mature long-term follow-up data rather than mechanistic inference alone.
Like a key that fits the lock but has not yet opened the door, MHRA authorisation is the necessary but not sufficient condition for patient access. For present-day haematologists, the authorisation is the starting point of a process, not the conclusion of one.
Related reading
Belantamab Mafodotin Gets First-in-World MHRA Approval in Myeloma
